Prostate Cancer

Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate cancer: scientific evidence and sharing of our experience.

Presentation of the interesting case of a patient suffering from castrate-resistant prostate cancer (CRPC) with bone metastasis, who received concomitant treatment with abiraterone acetate (AA) and radium-223.

Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome.

Radium-223 (Ra223) prolongs the survival and improves the quality of life of men with metastatic, castration-resistant prostate cancer (mCRPC) to bones. However, compared to other mCRPC therapies, using Ra223 comes with its unique challenges.

miR-1231 Is Downregulated in Prostate Cancer with Prognostic and Functional Implications.

Our study investigated the expression levels of miR-1231 in prostate cancer tissues and cell lines and explored its potential prognostic significance as well as its functional effects on prostate cancer cells.

Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment: A Population-based Study.

The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA).

Comparison of Initial Experience with Transrectal MRI Cognitive Guided Micro-ultrasound Biopsies versus Established Transperineal Robotic Ultrasound-Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.

We aimed to compare cancer detection rates (CDR) in patients who underwent MRI cognitive guided micro-ultrasound biopsy (MB) versus Robotic ultrasound-magnetic resonance imaging fusion biopsies (RFB) for prostate cancer (PCa).

Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy.

The addition of androgen deprivation therapy to radiation therapy (RT) improves survival in patients with intermediate- and high-risk prostate cancer (PCa), but it is not known whether combined androgen blockade (CAB) with a gonadotropin-releasing hormone agonist (GnRH-A) and a nonsteroidal antiandrogen improves survival over GnRH-A monotherapy.

Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis.

OBJECTIVE. Despite a substantial increase in the use of MRI for pretreatment evaluation of prostate cancer, its prognostic value in patients undergoing radiation therapy (RT) is not well known. Therefore, the purpose of this study was to systematically review the literature and perform a meta-analysis on the prognostic value of pretreatment MRI in patients with prostate cancer who underwent external beam radiation therapy (EBRT) or brachytherapy.

Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document.

The availability of a number of agents that are efficacious in patients with metastatic prostate cancer (mPC) has led to them being used sequentially, and this has prolonged patient survival. However, in order to maximize their efficacy, clinicians need to be able to obtain a reliable picture of disease evolution by means of monitoring procedures.

Comparison between Conventional IMRT Planning and a Novel Real-Time Adaptive Planning Strategy in Hypofractionated Regimes for Prostate Cancer: A Proof-of-Concept Planning Study.

In prostate cancer external beam radiation therapy (EBRT), intra-fraction prostate drifts may compromise the treatment efficacy by underdosing the target and/or overdosing the organs at risk. In this study, a recently developed real-time adaptive planning strategy for intensity-modulated radiation therapy (IMRT) for prostate cancer was evaluated in hypofractionated regimes against traditional treatment planning based on a treatment volume margin expansion.

Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy.

Currently, there is a dearth of data concerning the impact of hypogonadism on prostate cancer detection by imaging. In this study, we evaluated the performance of multiparametric MRI (mpMRI) and mpMRI-TRUS fusion biopsy in hypogonadal patients.

Effect of a Smoking Cessation Program on Sexual Function Recovery Following Robotic Prostatectomy at Kaiser Permanente Southern California - Beyond the Abstract

Sexual function decline in men is one of the most devastating side effects after robotic prostatectomy for prostate cancer. While urologists are apt to discuss and treat erectile dysfunction in patients following surgery, one of the most common causes of erectile dysfunction may often be overlooked: tobacco smoking.

Evaluating the measurement properties of the 26-item Expanded Prostate Cancer Index Composite (EPIC-26) with a multicenter cohort.

We aimed to evaluate the psychometric properties of the 26-item Expanded Prostate Cancer Index Composite (EPIC-26) for measuring the quality of life in patients treated for localized prostate cancer.

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.

Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and provides the opportunity to reduce target volume margins. We introduced IGRT methods using standard (IGRT-S) or reduced (IGRT-R) margins in a randomised phase 2 substudy within CHHiP trial.

Multiparametric MRI-Based Radiomics for Prostate Cancer Screening With PSA in 4-10 ng/mL to Reduce Unnecessary Biopsies.

Whether men with a prostate-specific antigen (PSA) level of 4-10 ng/mL should be recommended for a biopsy is clinically challenging.

To develop and validate a radiomics model based on multiparametric MRI (mp-MRI) in patients with PSA levels of 4-10 ng/mL to predict prostate cancer (PCa) preoperatively and reduce unnecessary biopsies.

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.

Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in metastatic castration-resistant prostate cancer.

Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique.

Purpose: To explore whether prostatectomized men report improved post-operative erectile function and urinary control dependent on the application of intra-operative frozen section examination (NeuroSAFE) during nerve-sparing radical prostatectomies (NS-RPs).

Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered A “Negative Core” in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis – Beyond the Abstract

Pre-radical prostatectomy (RP) risk nomograms for prostate cancer (PCa) have been constructed to provide prognostic information regarding a patient’s oncologic outcomes. Specifically, these nomograms predict the risk of lymph node involvement (LNI) in PCa patients, which subsequently informs a surgeon’s decision to perform pelvic lymph node dissection (PLND) at the time of RP.1,2 In the current era, where Gleason Grade Group (GG) 1 PCa is increasingly deemed clinically insignificant, established nomograms may be suboptimal in estimating final RP pathology outcomes for men diagnosed with PCa.

Radiotherapy in Metastatic Castration Resistant Prostate Cancer Patients with Oligo-Progression during Abiraterone-Enzalutamide Treatment: A Mono-Institutional Experience - Beyond the Abstract

Castration resistant prostate cancer patients are a niche of patients affected by progressive prostate cancer despite androgen deprivation therapy and a serum testosterone value < 50 mg/dl.

Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy.

Intermediate clinical endpoints (ICEs) might aid in trial design and potentially expedite study results. However, little is known about the most informative ICE for patients receiving salvage radiation therapy (sRT) after radical prostatectomy.

The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.

We aimed to evaluate the treatment sequence for patients with metastatic castration-resistant prostate cancer (mCRPC) in real-world practice and compare overall survival in each sequential therapy.

We retrospectively evaluated 146 patients with mCRPC who were initially treated with androgen deprivation therapy as metastatic hormone-naive prostate cancer in 14 hospitals between January 2010 and March 2019.